follow us
disclaim warranti liabil
due number sourc inform servic acquisdata pti ltd servic obtain
inher hazard electron distribut may delay omiss inaccuraci inform
servic acquisdata pti ltd affili agent sale repres distributor licensor
warrant accuraci complet current merchant abil fit particular purpos
inform servic avail acquisdata pti ltd servic event acquisdata pti ltd
affili agent sale repres distributor licensor liabl license anyon els loss
injuri caus whole part conting beyond control procur compil interpret edit write
report deliv inform servic acquisdata pti ltd servic event acquisdata
pti ltd affili agent sale repres distributor licensor liabl license anyon els
decis made action taken license relianc upon inform servic consequenti
special similar damag even advis possibl damag license agre liabil
acquisdata pti ltd affili agent sale repres distributor licensor aris kind
legal claim whether contract tort otherwis way connect acquisdata pti ltd servic shall
exceed amount license paid use acquisdata pti ltd servic twelv month immedi
preced event give rise claim
sale billion reflect strong growth oper growth adjust oper growth
inclus overal estim neg impact pandem
ep increas adjust ep increas
dividend increas announc
long term fundament remain intact guidanc lower reflect impact relat invest
first-quart compani also announc earlier today board director declar
increas quarterli dividend rate per share per share new rate indic
dividend annual basi per share compar previou rate per share
johnson johnson century-plu histori lead time great challeng mobil
resourc across compani fight pandem said gorski chairman chief
execut offic johnson johnson built time like leverag scientif expertis
oper scale financi strength effort advanc work lead vaccin candid
commit begin product risk immin bring afford access vaccin
public not-for-profit basi emerg pandem use
mr gorski continu proud amaz level dedic wit
employe focus deliv commit respons patient
consum serv strong perform first quarter reflect effort team around
world sustain busi model today board director approv increas
quarterli dividend consecut year underscor commit deliv valu
sharehold confid busi futur
consum world-wide oper sale exclud net impact acquisit divestitur grew
driven primarili over-the-count product includ tylenol motrin analges upper respiratori
product includ zyrtec digest health product zarbe natur contributor growth
listerin mouthwash oral care product neutrogena aveeno skin health/beauti product
well stayfre intern women health consum result across major
franchis posit impact increas demand relat pandem
pharmaceut world-wide oper sale exclud net impact acquisit divestitur grew
driven stelara ustekinumab biolog treatment number immune-medi inflammatori
diseas darzalex daratumumab treatment multipl myeloma imbruvica ibrutinib oral once-
daili therapi approv use treat certain b-cell malign type blood lymph node cancer invega
antipsychot treatment schizophrenia adult erleada apalutamid next-gener androgen
receptor inhibitor treatment patient prostat cancer opsumit macitentan oral endothelin
receptor antagonist indic treatment pulmonari arteri hypertens delay diseas progress
tremfya guselkumab biolog treatment adult live moder sever plaqu psoriasi
prezista/prezcobix/rezolsta/symtuza treatment human immunodefici viru type
infect growth partial off-set biosimilar gener competit declin primarili intern
velcad bortezomib proteasom inhibitor treatment multipl myeloma remicad infliximab
biolog approv treatment number immune-medi inflammatori diseas procrit epoetin
alfa treatment chemotherapy-induc anemia patient chronic kidney diseas
medic devic world-wide oper sale exclud net impact acquisit divestitur declin
driven estim net neg impact pandem associ deferr medic
procedur surgeri orthopaed intervent solut vision busi
johnson johnson provid gaap financi measur forward-look basi compani
unabl predict reason certainti ultim outcom legal proceed unusu gain loss
acquisition-rel expens purchas account fair valu adjust without unreason effort
item uncertain depend variou factor could materi johnson johnson result comput
accord
oper sale growth exclud impact translat currenc adjust oper sale growth exclud
net impact acquisit divestitur translat currenc well adjust net earn adjust
dilut earn per share adjust oper dilut earn per share exclud after-tax intang
amort expens special item non-gaap financi measur consid
replac read togeth compar financi measur except
guidanc measur reconcili non-gaap financi measur directli compar gaap
financi measur found accompani financi schedul earn releas investor
section compani websit quarterly-result
copi financi schedul accompani earn releas avail compani websit
quarterly-result schedul includ supplementari sale data condens consolid statement
earn reconcili non-gaap financi measur sale key products/franchis addit
inform johnson johnson includ adjust incom tax segment pharmaceut pipelin
select compound late stage develop copi today earn call present also found
investor section compani websit quarterly-result
acquisdata proud host leagu estim want opportun win free
subscript join acquisdata media telecommun leagu
johnson johnson believ good health foundat vibrant live thrive commun forward
progress that year aim keep peopl well everi age everi stage
life today world largest broadli base healthcar compani commit use reach
size good strive improv access afford creat healthier commun put healthi
mind bodi environ within reach everyon everywher
johnson johnson incorpor state new jersey
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
abbott global diversifi healthcar compani central purpos help peopl live healthiest possibl
live offer broad portfolio market-lead product align favor long-term healthcar trend
develop develop market build strong foundat year success abbott
pois deliv top-tier growth expand margin strong cash flow increas return sharehold
compani take toughest health challeng treat diseasesw aim make
remark impact peopl live highli focus research-driven biopharmaceut
today employe around world focu deliv transform medicin therapi
allergan plc nyse agn headquart dublin ireland global pharmaceut leader focus
develop manufactur commerci brand pharmaceut devic biolog surgic regen
medicin product patient around world
one world largest pharmaceut servic compani serv unit state
canada select global market focu pharmaceut suppli channel servic
pharmaceut manufactur healthcar provid compani servic solut rang nich premium
logist pharmaceut packag reimburs pharmaceut consult servic scale
posit healthcar industri valu bring channel help busi continu
commit unlock potenti biolog patient suffer seriou ill discov
develop manufactur deliv innov human therapeut approach begin use tool like
advanc human genet unravel complex diseas understand fundament human biolog
global science-l biopharmaceut busi innov medicin use million
time world around us chang burden diseas increas respond
increas focu growth innov patient-centr technolog digit
data advanc cutting-edg scienc
bausch health compani inc formerli valeant pharmaceut multi-national specialti pharmaceut
compani base laval canada bausch health focus improv peopl live health care
product deliv commit patient health care provid stakehold societi
build innov compani dedic advanc global health
baxter touch live million peopl around world everi day product therapi found
throughout hospit clinic er pharmaci icu well advanc patient
care home inc fortun american health care compani headquart
bristol-my squibb differenti compani led uniqu biopharma strategi leverag reach
resourc major pharma compani pair entrepreneuri spirit agil biotech firm work
everi day deliv innov medicin patient seriou life-threaten diseas
lilli found colonel eli lilli man commit creat high-qual medicin met real need
era unreli elixir peddl question charact charg gener employe
follow take find make better better
consid founder industri genentech member roch group deliv
promis biotechnolog year
genentech biotechnolog compani dedic pursu groundbreak scienc discov develop
medicin peopl seriou life-threaten diseas transform discoveri includ first
target antibodi cancer first medicin primari progress multipl sclerosi
science-l global healthcar compani special purpos help peopl feel better live
glaxosmithklin plc form result merger glaxo wellcom plc smithklin
beecham plc although histori trace back year london plough court pharmaci
era unpreced complex healthcar patient care mani
organ deliv care need get much healthier
vision improv care everi set one product one partner one patient time
make happen everi day touch virtual everi aspect healthcar
global healthcar compani histori work make differ
make differ live peopl global innov medicin vaccin anim health
product commit premier research-intens biopharmaceut compani dedic
provid lead innov solut today futur
discov develop provid innov product servic save improv live around world
novarti creat merger ciba-geigi sandoz novarti predecessor compani
trace root back year rich histori develop innov product
purpos reimagin medicin improv extend peopl live use innov scienc
technolog address societi challeng healthcar issu discov develop breakthrough
treatment find new way deliv mani peopl possibl also aim reward
invest money time idea compani
novo nordisk drive chang defeat diabet seriou chronic condit
novo nordisk global healthcar compani year innov leadership diabet care
heritag given us experi capabl also enabl us help peopl defeat seriou chronic
condit rare bleed disord growth hormon relat disord obes
headquart denmark novo nordisk employ approxim peopl countri market
product countri
start humbl begin year ago rural michigan today one largest
luther perrigo owner gener store apple-dri busi idea packag
distribut patent medicin household item countri store luther launch privat label concept
way enhanc custom loyalti addit cost offer imprint store name label
epsom salt sweet oil bay rum dozen wet dri good stock gener store
pfizer inc research-bas global biopharmaceut compani appli scienc global resourc
bring therapi peopl extend significantli improv live discoveri develop
manufactur healthcar product global portfolio includ medicin vaccin well mani
regeneron pharmaceut inc lead scienc technolog compani deliv life-
transform medicin seriou diseas inc compani headquart eastview
near tarrytown new york found physician-scientist year ago science-driven approach result
six fda-approv medicin numer product candid rang diseas includ asthma pain
cancer infecti diseas
field human health undergo profound scientif technolog chang point way major
therapeut innov patient
sanofi innov dna mission har new technolog new way work find
healthcar solut around world research develop strategi innov view
three angl scienc technolog digit
build strong global footprint size scale teva reaffirm commit place peopl
center strategi enabl mani possibl live better healthier day develop
produc market afford high qualiti gener drug well innov specialti pharmaceut
activ pharmaceut ingredi
biopharmaceut compani across america peopl go work everi day mission advanc
innov treatment cure make differ million patient live
commit ensur patient access medicin preserv strong economi support vibrant
research valuabl job also stand behind medicin creat valu provid
patient across health care system
new era medicin breakthrough scienc transform care approach treat
patient robust invest research develop biopharmaceut compani result
advanc discoveri unlik anyth weve seen applic genom develop person
medicin enabl physician tailor treatment uniqu need patient immunotherapi
har patient immun system fight variou condit includ cancer rare diseas
last decad alon biopharmaceut compani invest half trillion dollar invest
begin yield result open door entir new way tackl complex difficult
treat diseas time
progress see today revolution treat diseas save patient live improv qualiti life
public health across broad rang chronic rare condit new era medicin mani diseas
previous regard deadli manag potenti curabl today medicin
clinic develop around world across medicin pipelin clinic develop
potenti first-in-class treatment repres entir new approach treat diseas futur
never brighter research explor new frontier year ago may regard
scienc fiction transform patient live
new era medicin isnt good news healthit good news health care system societi
new innov medicin keep patient healthi hospit reduc need costli emerg
room visit hospit stay surgeri long-term care save money patient nation health
system look forward medicin best bet confront countri biggest health cost driver chronic
diseas condit cancer diabet heart diseas lead caus death disabl
unit state patient condit account health care spend iv continu
advanc treatment indispens address societi health econom challeng year
invest biopharmaceut innov improv save live also drive tremend contribut
american economi america role leader medic innov biopharmaceut
compani invest billion unit state industri america
industri support million job across countri employe across compani
go work everi day research develop new treatment cure patient occur even face
continu setback develop timelin extens cost high rate scientif
new medicin transform care patient fight debilit diseas like cancer hepat heart diseas
mani rare condit yet midst progress spend retail physician-administ medicin
continu repres overal health care spend next decad mani new medicin
revolution care patient yet spend medicin project continu remain small stabl
share health care spend occur market-bas system unit state promot
incent continu innov increas patient access need medicin leverag competit
control cost
 market highli competit robust competit brand gener andincreasinglybiosimilar
altern result medicin price fall dramat competit occur among brand name medicin
price fall even gener introduc market fact prescript fill patient
unit state gener typic cost fraction price initi brand medicin ix expect
dynam continu year ahead sinc billion brand sale project face gener
biosimilar competit
anoth reason current marketplac medicin success control cost health insur
pharmaci benefit manag pbm power sophist purchas use leverag negoti
discount rebat list price medicin today top three pbm manag
prescript fill unit state xi averag list price medicin given
rebat discount insur compani govern pbm entiti suppli chain often
requir larg rebat medicin cover xii fact evid suggest negoti discount rebat
price concess doubl sinc total billion
continu growth rebat discount keep prescript medicin price growth slowest rate
year doesnt feel way mani patient often negoti save make way
patient increasingli ask pay pocket innov medicin unlik care receiv
in-network hospit physician offic patient high deduct coinsur pay cost share base
list price medicin even though insur may receiv steep discount half commerci
insur patient out-of-pocket spend brand medicin base full list price xiv mean patient
high deduct health plan pay list price month medicin may pay hundredsor even
thousandsmor year insur pay medicin
insur increasingli expos patient list price medicin patient seen out-of-pocket cost
continu grow pharmaci commerci insur patient deduct seen out-of-pocket
cost brand medicin increas sinc
though rebat discount grown substanti health plan typic use portion negoti
rebat reduc premium enrolle rather directli lower cost patient face high cost-shar
due deduct coinsur creat system payer requir patient pay pocket
rebat save spread among health plan enrolle form lower premium ask sicker
patient subsid premium healthier enrolle exact opposit health insur suppos
chang need ensur billion negoti rebat discount price concess
use lower cost patient pharmaci counter research show high cost share associ
lower medic adher increas abandon rate put patient abil stay need
therapi risk share negoti discount could save certain commerci insur patient high deduct
coinsur annual increas premium less xx medicar
part polici ensur save negoti discount pass medicar beneficiari would also
improv afford senior strengthen competit incent part program exampl typic
medicar beneficiari diabet take five medicin could save year out-of-pocket cost
america biopharmaceut compani commit work policymak stakehold advanc
market-bas solut aim toward ensur patient access need treatment support continu
innov drive valu health care system address misalign suppli chain incent
statu quo work patient misalign incent health care system need chang
rebat price concess payer receiv biopharmaceut compani use lower
cost share patient pharmaci counter need improv afford predict
cost senior medicar part current limit out-of-pocket expens adopt out-
of-pocket cap medicar part would align benefit commerci insur market ensur
beneficiari face catastroph ill abl afford treatment provid patient
transpar medicin cost phrma member voluntarili direct patient link cost inform
direct-to-consum dtc televis advertis phrma also launch medicin assist tool
provid link referenc dtc televis advertis help patient connect financi assist
make medicin afford move toward health care system focus result measur
valu eye patient enabl privat sector develop new better way pay
medicin move toward value-driven health care system includ develop data provid
patient physician easy-to-us inform differ medicin work creation better measur
qualiti care take account patient feel reform allow new way insur pay
medicin advanc research method relat valu assess encompass outcom
matter patient famili import step toward goal
commit advanc market-bas reform promot competit modern drug discoveri
develop process get medicin approv effici ensur safeti need modern
drug discoveri develop process equip regul new technolog expertis keep
centuri scienc also need ensur time review approv gener biosimilar medicin
patient benefit less expens gener biosimilar medicin replac treatment follow expir
patent data protect addit unit state must continu incentiv medic innov
competit strong intellectu properti incent enforc within outsid unit
market-bas health care system work well control cost done help work even
better patient current system creat misalign incent pbm other suppli chain
favor medicin high list price rebat impact patient afford reform need
prevent pbm other suppli chain paid list price medicin instead fee base
valu servic provid wrong way address misalign incent greater govern
intervent marketplac negoti adopt harm practic countri restrict patient
access need medicin strengthen health care system must also address misalign profit incent
fuel hospit markup medicin provid consolid address misalign incent
present opportun reduc largest fastest contributor health care costshospit spend
pharmaceut research manufactur america phrma
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
